Redux Recall and Side Effects


Related Ads

redux, which was also known as Dexfenfluramine, was a prescription drug available to U.S. consumers until 1997, when a domestic Redux recall resulted in the drug being pulled from U.S. markets, and in turn, virtually across the globe.  Initially, Redux was used in conjunction with other popular weight loss medications as part of a comprehensive weight loss program for patients.  The drug received FDA approval in the mid-1990’s, however, was pulled from the market in a little over two years after medical studies and patient concerns regarding the drug’s safety were substantiated.  One common drug associated with Redux was the popular weight loss drug Fen-Phen, which the key component of Redux, Dexfenfluramine, was the “Fen” position of Fen-Phen.  The makers of Redux, Interneuron Pharmaceuticals and the marketers of the drug, Wyeth-Ayerst Laboratories, have since settled class action claims made by patients harmed by taking Redux.

Risks and Symptoms of Redux

Redux posed significant health hazards to patients taking this drug in the mid to late 1990’s.  Common claims against the makers and marketers of Redux revolve around the increase risk of heart problems related to patients taking the drug.  The anorectic drug was one of numerous weight loss medications pulled from the market stemming from studies showing the drug hardened the lining of heart valves, which led to malfunctions in the heart, causing irregular heartbeats, cardiovascular issues, and death.  Studies of patients taking Redux at the time noted that nearly one-third of all patients taking the drug exhibited abnormal and potentially fatal echocardiograms in medical studies.  

Redux Claims and Lawsuits

Following the warnings and removal of Redux from the market by the FDA, a slew of lawsuits were filed against the makers of Redux, Interneuron Pharmaceuticals and the marketers of the drug, Wyeth-Ayerst Laboratories.  Eventually, the federal courts combined the vast majority of these claims into a class action suit.  The results of the class action efforts caused the makers of Fen-Phen, Redux, and other similar drugs to settle claims at the amount of twelve billion dollars, stemming from claims made by nearly six million patients.  Specifically, patients harmed by the use of Redux were allotted settlement awards ranging from one and half million dollars down to five thousand dollars.  The claims settlement ceased accepting new claims around mid-2002.  However, individual claims most likely are still eligible to be filed under certain circumstances, including joining the past settlement agreement against these companies in case-specific instances.

Legal Help from a Lawyer

Given the past-due nature of Redux claims today, individuals affected harmfully by these drugs should immediately seek counsel from an attorney.  Drug liability claims may still be eligible for compensation under certain circumstances, including those where medical damages did not appear until several years after the stopping of Redux use.

This article is provided for informational purposes only. If you need legal advice or representation,
click here to have an attorney review your case .
NOLODRUPAL-web1:DRU1.6.12.2.20161011.41205